

Title: Bowel Function After Watch-and-Wait Versus Low Anterior Resection for Rectal Cancer:
A Rapid Scoping Review Protocol

Authors:

Jessica Colin Escobar, MD, MBA
Department of Surgery
Northwestern University Feinberg School of Medicine, Chicago, IL
jessica.colinescobar@nm.org

Amy Halverson, MD, MEd
Department of Surgery
Northwestern University Feinberg School of Medicine, Chicago, IL
amy.halverson@nm.org

Annie B Wescott, MLIS
Galter Health Sciences Library & Learning Center, Feinberg School of Medicine, Northwestern
University
annie.wescott@northwestern.edu

Introduction

The management of rectal cancer has evolved with the advances of neoadjuvant therapy. These advances have allowed patients that achieve clinical complete response after total neoadjuvant therapy to be managed nonoperatively using the “watch-and-wait” (WW) strategy.¹ Using this strategy, patients with no evidence of residual tumor on digital rectal exam, endoscopy, and pelvic MRI are closely monitored rather than undergoing low anterior resection (LAR).¹ Oncologic outcomes and overall survival, are largely comparable between WW and surgical resection.¹⁻³ WW carries a higher rates of local regrowth, though most cases can be effectively salvaged.^{1,2} The WW strategy aims to preserve organ function and avoid surgical morbidity while maintaining oncologic safety.

Although LAR is a type of sphincter-preserving surgery, it carries a substantial risk of postoperative bowel dysfunction.⁴ The constellation of these symptoms is known as low anterior resection syndrome (LARS) which includes unpredictable bowel function, issues with emptying, frequent and painful bowel movements, urgency, incontinence, and soiling.⁵ It is estimated that LARS can affect up to 90% of patients after sphincter-preserving surgery and can cause significant impairment in physical, social, and emotional function.⁶ Many patients feel unprepared for the extent of these symptoms, highlighting the need for long-term support, proactive follow-up, and multidisciplinary management to help patients adapt and improve their quality of life.⁷

Given this burden, WW offers a theoretical functional advantage by avoiding surgical disruption of the rectum and anal sphincter complex. However, evidence supporting this assumption remains inconsistent and fragmented. Understanding and comparing these outcomes is essential for patient-centered decision making, allowing clinicians and patients to balance oncologic safety with functional preservation and individual preferences.

This rapid scoping review aims to map the current evidence on bowel function following watch-and-wait versus low anterior resection for rectal cancer. Specifically, we will (1) identify and categorize the instruments used to assess bowel function, (2) summarize reported functional outcomes, and (3) describe interventions reported for patients with bowel dysfunction.

Methods

Protocol: This rapid scoping review protocol was formulated based on the PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation.⁸

Eligibility Criteria:

Inclusion criteria:

- Study must include adult (>18-year-old) patients with rectal adenocarcinoma managed with WW (organ preserving) or LAR (sphincter-sparing).
- Study must assess bowel function using validated and non-validated instruments, reported bowel function outcomes, or described management of bowel dysfunction.
- Study must be in English
- Studies were limited by publication date between January 2015 to October 2025.

Exclusion criteria:

- Studies limited to metastatic disease, palliative management, and oncologic outcomes without bowel function assessment.
- Studies validating bowel function instruments in a different language.
- Conference abstracts, case reports or case series with less than 5 patients, and commentaries.
- Meta-analyses or systematic reviews, however, included studies may be included if meeting inclusion criteria.

Information Sources:

To identify potentially relevant documents, the following databases were searched from January 2015 to October 2025: Ovid MEDLINE, Embase (Elsevier), and Web of Science (Clarivate). The search strategies were drafted by an experienced librarian, Annie B Wescott, and further refined through team discussion. The final search results were exported to EndNote, and duplicates were removed.

Search Strategy:

Our search combines database-specific controlled vocabulary and natural language terms. The search was initially constructed for use in Ovid MEDLINE (search table included below). The search will be translated for each database, and search strings will be reported in our final manuscript. Currently, we do not have plans to review grey literature for this topic.

1	<i>exp Rectal Neoplasms/</i>	58069
2	<i>((rectal or rectum) adj2 (cancer* or tumor* or tumour* or adenocarcinoma*)).ti,ab.</i>	39611
3	<i>1 or 2</i>	71182
4	<i>exp Defecation/</i>	8016

5	<i>exp Low Anterior Resection Syndrome/</i>	108
6	<i>exp "Watchful Waiting"/</i>	5984
7	<i>4 or 5 or 6</i>	14099
8	<i>exp "Patient Reported Outcome Measures"/</i>	20011
9	<i>exp "Surveys and Questionnaires"/</i>	1342671
10	<i>8 or 9</i>	1342671
11	<i>7 and 10</i>	1421
12	<i>(COREFO or MSK-BFI or POLARS or FIQL or ICIQ-B or Vaizey or Wexner).ti,ab.</i>	1529
13	<i>((biofeedback-therapy or pelvic-floor-muscle-training or pelvic-floor-rehabilitation or percutaneous-tibial-nerve-stimulation or resection* or sacral-nerve-stimulation or trans-anal-irrigation or transanal-irrigation or watch-and-wait or watchful-waiting or LARS or bowel-function or colorectal-function* or anal-function* or rectal-function* or intestine-function* or intestinal-function* or anorectal-function* or bowel-dysfunction* or colorectal-dysfunction* or anal-dysfunction* or rectal-dysfunction* or intestine-dysfunction* or intestinal-dysfunction* or anorectal-dysfunction*) adj3 (score* or instrument* or tool or tools or evaluate or evaluates or evaluation or questionnaire* or scale* or subscale* or assessment*)).ti,ab.</i>	5035
14	<i>11 or 12 or 13</i>	7633
15	<i>3 and 14</i>	935
16	<i>limit 15 to yr="2015 -Current"</i>	689

Selection of Sources of Evidence:

At least two reviewers will work sequentially to evaluate titles, abstracts, and full text of all publications identified by our searches for relevant publications that meet our inclusion criteria. We will use Rayyan, an online screening platform, to screen studies. We will resolve disagreement on study selection by consensus and discussion with each other and other pre-determined reviewers. A PRISMA flow diagram will be employed to show steps in the inclusion process, as well as rationale for the exclusion of any articles.

Data Charting Process:

A data-charting form will be developed jointly by two reviewers to determine which variables to extract. Data extraction from each article will be performed independently by two authors, results will be discussed, with the created form for data extraction changed iteratively as needed.

Data Items:

Data of interest will capture study characteristics (author, year, country, study design, sample size), treatment group (WW, LAR, or both), timing of bowel function assessment, follow-up duration, bowel function assessment instrument(s), functional domains evaluated, bowel function outcomes, reported management/interventions strategies for bowel dysfunction.

Synthesis of Results:

We plan to summarize the findings in several tables.

- Table 1 will outline key study characteristics including study design, sample size, management strategy (WW, LAR, or both), timing of bowel function assessment, follow-up duration, and the bowel function assessment instruments used.
- Table 2 will detail the functional assessment instruments, frequency of use across studies, domains measured, application to WW and/or LAR cohorts, and if the tool is validated.
- Table 3 will summarize reported management strategies of bowel dysfunction. It will specify intervention type and reported efficacy.

References

1. Langenfeld SJ, Davis BR, Vogel JD, et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Rectal Cancer 2023 Supplement. *Diseases of the Colon & Rectum*. 2024;67(1):18-31. doi:10.1097/dcr.0000000000003057
2. Garcia-Aguilar J, Patil S, Gollub MJ, et al. Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. *J Clin Oncol*. Aug 10 2022;40(23):2546-2556. doi:10.1200/jco.22.00032
3. Dattani M, Heald RJ, Goussous G, et al. Oncological and Survival Outcomes in Watch and Wait Patients With a Clinical Complete Response After Neoadjuvant Chemoradiotherapy for Rectal Cancer: A Systematic Review and Pooled Analysis. *Ann Surg*. Dec 2018;268(6):955-967. doi:10.1097/sla.0000000000002761
4. Hupkens BJP, Martens MH, Stoot JH, et al. Quality of Life in Rectal Cancer Patients After Chemoradiation: Watch-and-Wait Policy Versus Standard Resection - A Matched-Controlled Study. *Dis Colon Rectum*. Oct 2017;60(10):1032-1040. doi:10.1097/dcr.0000000000000862
5. Rosen H, Sebesta CG, Sebesta C. Management of Low Anterior Resection Syndrome (LARS) Following Resection for Rectal Cancer. *Cancers (Basel)*. Jan 27 2023;15(3)doi:10.3390/cancers15030778
6. Bolton WS, Chapman SJ, Corrigan N, et al. The Incidence of Low Anterior Resection Syndrome as Assessed in an International Randomized Controlled Trial (MRC/NIHR ROLARR). *Ann Surg*. Dec 1 2021;274(6):e1223-e1229. doi:10.1097/sla.0000000000003806
7. Ribas Y, Muñoz-Duyos A, Franquet M, et al. Enhancing support for patients with low anterior resection syndrome: insights and educational resources from the LARSCAT project. *Int J Colorectal Dis*. Dec 5 2024;39(1):196. doi:10.1007/s00384-024-04775-9
8. Tricco AC, Lillie E, Zarin W, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med*. Oct 2 2018;169(7):467-473. doi:10.7326/m18-0850